

Closing share Price (30/08/2022)

**EUR 72.50**

Target valuation range

**EUR 81.00 - 99.00**

Risk	Low
Reuters	LUX.LU
Bloomberg	LXMP LX
Shares number (m)	20.15
Market cap. (m)	1,461
NAV 31/08/2022	104.80
(Discount)/Premium	-30.8%
1 year price perf.	6.6%
Diff. with Euro Stoxx	23.1%
Volume (sh./day)	1,252
H/L 1 year	79.50 - 70.00
Free Float	24.2%
Foyer Finance	50.4%
Sofina Group	6.1%
Stable Shareholders	16.6%
Treasury Shares	2.7%

### Company description

Luxempart is a Luxembourg based investment holding company with more than 25 years of existence. Luxempart invests in several European countries, mainly in the DACH region, Luxembourg, Belgium, France and Northern-Italy.



### Analyst:

**Joren Van Aken**

Equity Analyst

+32 2 662 88 83

j.vanaken@degroofpetercam.com

## Luxempart

### Putting the money where their mouth is

This report is considered as a marketing communication. It has been commissioned and paid for by Luxempart and has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is also not subject to any prohibition on dealing ahead of the dissemination of investment research.

### Acquires a stake in Nexus, leading supplier of software for Healthcare sector

Nexus AG, a German small cap (market cap ~EUR 800m) and one of the leading European suppliers of software solutions in the healthcare sector, announced a capital increase through the issuance of 1.45m shares. This transaction will increase the share capital by around 9.17% to 17,264,695 outstanding shares.

The buyer of the shares is Luxempart which will acquire all 1.45m shares at a price of EUR 50 p/s. Nexus plans to use the proceeds to finance further growth. For Luxempart, this constitutes a EUR 72.5m investment (=50\*1.45) for which they will receive a ~8.4% stake in the company. Nexus plans to use the proceeds to finance further growth.

### Investment that fits perfectly within Luxempart's strategy

For Luxempart, this constitutes a EUR 72.5m investment (=50\*1.45) while also providing them with an ~8.4% stake in the company. This transaction fits well within Luxempart's investment strategy as the company primarily looks for small cap companies in the Benelux & DACH region. Both Nexus & Luxempart have confirmed their intention of Luxempart being an anchor shareholder for the company. Other large shareholders are Brown Capital and Fidelity, both with a ~10% stake as well. As mentioned in the press release: "The company has achieved a strong profitable growth track record over the last 20 years with a sales CAGR of 16% driven by a mix of organic growth and continuous bolt-on acquisitions."

### Putting cash position to work

As we published in our report of August 29, Luxempart disposes of a significant net cash position (~20% of NAV, >EUR 400m). Management had already stated that they were not planning on staying on the side lines in the current environment.

In our report we also highlighted that, as multiples in listed markets have come down more than in private ones, Luxempart might be on the lookout for new listed companies to add to its portfolio.

EUR	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
End FY Price	50.50	53.00	49.00	74.50	-	-	-
End FY NAV	70.09	78.40	85.11	107.80	-	-	-
End FY Discount	-27.9%	-32.4%	-42.4%	-30.9%	-	-	-
EPS	3.44	10.31	7.80	24.81	-	-	-
Cash EPS	-	-	-	-	-	-	-
Div.	1.41	1.48	1.60	1.80	1.94	2.10	2.27
Y/Y	5.0%	5.2%	8.1%	12.5%	8.0%	8.0%	8.0%
Payout	40.9%	14.4%	20.5%	-	-	-	-
Yield	2.9%	2.8%	3.3%	2.4%	2.7%	2.9%	3.1%

## Facts continued:

Nexus will immediately become the largest listed line in Luxempart's portfolio (39% of listed portfolio & ~4% of total portfolio i.e. GAV). This is once again in line with previous guidance of management which had stated its ambition to streamline its listed portfolio by increasing the concentration of the portfolio on a smaller number of investments. This also allows them to take larger stakes in companies that potentially can offer them a board seat.

## Our view: Anchor shareholder in decade-long compounder

Luxempart is immediately putting their money where their mouth is with a transaction that fits perfectly within their investment strategy. With this one investment, Luxempart immediately puts about 17.5% of its net cash to use, bringing the net cash position down to about 15.9% of the NAV.

We expect additional investments in the next 12 months as management will put its cash position to work.

A remarkable side note is that another Benelux investment company, namely Quest for Growth, is also a shareholder of Nexus AG, albeit with a smaller position (54k shares).

We reiterate our valuation range of EUR 81 to EUR 99 p/s which still offers 11.7% to 36.6% of upside.

Exhibit 1 NAV Luxempart				
Participations	Spot value (€m)	Per share	% of GAV	12m Target
<b>Direct Investment (Listed)</b>	111.5	5.5	7%	117.1
<b>Direct Investments (Private)</b>	1,163.6	57.7	68%	1,303.2
of which Foyer (DPe)	513.0	25.5	30%	559.2
<b>Investment Funds</b>	439.1	21.8	26%	487.4
<b>Gross Asset Value (GAV)</b>	<b>1,714.2</b>	85.1	<b>100%</b>	<b>1,907.7</b>
Net cash	433.1	21.5		433.1
<b>Net Asset Value (NAV)</b>	<b>2,147.3</b>	106.6		<b>2,340.8</b>
per share	106.6			116.2
<b>Share price</b>	73.0			
	<b>Current</b>	<b>Hist. average</b>	<b>Target</b>	
<b>Discount</b>	-31%	-30%	-15%	
<b>Target range in EUR</b>		<b>81</b>	<b>99</b>	

Source: Degroof Petercam estimates


### Share details Luxempart

Share Price	72.50
NAV	104.8
Prem/(Disc)	-30.8%
Target	-15%
Dividend	1.80
Yield	2.5%
Target range	EUR 81-99

Last updated

31/08/2022

### NAV distribution




### Historic discount average


5Y average	-27.6%
10Y average	-31.5%

■ Foyer ■ Funds ■ Listed ■ Other Private ■ Cash


### 5Y Share Price / NAV / Discount evolution




### 10Y Share Price / NAV / Discount evolution



### Sector distribution direct investments



### Geographical distribution direct investments



## Commissioned Research

Degroof Petercam is commissioned by this company to publish research and is paid for this service.

## Disclosures applicable when indicated on the front page

1. Degroof Petercam acts as a liquidity provider for this company and is paid for these services.
2. Degroof Petercam has provided corporate finance services in the past 12 months for this company.

## General disclaimer

### About Degroof Petercam

This report has been prepared by Bank Degroof Petercam SA/NV ("Degroof Petercam").

Degroof Petercam is a financial institution authorised by and under the prudential supervision of, as a credit institution, the National Bank of Belgium and under the supervision of the Financial Services and Markets Authority. It has its registered office at 44, rue de l'Industrie, 1040 Brussels and is registered with the crossroads bank for enterprises under number 0403.212.172.

### No investment research

This report is considered as a marketing communication. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

### Not approved by the competent regulator

This report is not subject to any statutory prior approval requirement by a competent supervisory authority. As a result, this report has not been, and will not be submitted for approval to any competent supervisory authority.

### Content of the report

This report has been prepared by the sell-side research team of Degroof Petercam. All opinions, views, estimates and projections included herein reflect the personal views of the author on the subject company and related securities as of the date of this report. This report does not necessarily reflect the views of Degroof Petercam as institution and is subject to change without notice. The analyst(s) claim(s) furthermore not to have any meaningful financial interest in any of the aforementioned companies, not to be conflicted and not to have accepted any inducement from any person with a material interest in the subject company of the report at hand. The remuneration of the analysts is subject to the remuneration policy of Degroof Petercam and can be consulted [here](#).

The information and opinions contained in this report have been compiled or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness.

### Validity of the report

Any information, opinion or estimate contained in the present report is, regardless of source, given in good faith and may only be valid as of the date on which this report is published and is subject to change. The value of any investment may also fluctuate as a result of market changes. Degroof Petercam is not obliged to inform the recipients of this report of any change to such opinions or estimates.

### Not for retail clients

This report is meant exclusively for professional clients or eligible counterparties (as defined in the Markets in Financial Instruments Directive 2014/65/EU) and is not intended for retail clients use.

### Review by the subject company of this report

Degroof Petercam reserves the right to submit a draft of the research report (excluding – where relevant - the target valuation range/fair value and the recommendation) for review to the subject company with the sole purpose of correcting any inadvertent material factual inaccuracies.

### Conflict of interest

It should be noted that Degroof Petercam and the subject company have entered into an agreement relating to the production of this report. Degroof Petercam has received a remuneration from the subject company for the drafting and dissemination of this report.. This remuneration is (i) a fixed fee which has been agreed between the subject company and Degroof Petercam prior to the drafting and publication of this report and (ii) under no circumstances positively or negatively influenced by the content of this report.

Due to the broad activities of the group to which Degroof Petercam belongs, it may occur that Degroof Petercam or any of its affiliates:

- holds positions or effect transactions in the securities of the company mentioned herein or any member of its group;
- performs or seeks to perform investment banking services for such companies (such as corporate finance advice services);
- acts as a market maker or a liquidity provider for the securities of the company mentioned herein;
- performs any other services it is legally entitled to provide;
- hold a mandate in the subject company;
- hold a significant stake in the subject company.

In this regard, Degroof Petercam is required to have arrangements in place to identify, prevent and manage conflicts of interest between itself and clients and between different clients. Degroof Petercam operates in accordance with a conflicts of interest policy under which Degroof Petercam has identified those situations in which there may be a conflict of interest and, in each case, the steps taken to manage that conflict. Degroof Petercam has taken reasonable care to ensure that objectivity of this research report and the independence of the author are ensured and it has put in place several arrangements (such as internal policies and procedures) in order to manage potential conflicts of interests. Degroof Petercam has for example implemented

a remuneration policy, a personal account dealing procedure and several organizational measures such as Chinese Walls which are designated to prevent against the wrongful disclosure and use of confidential and sensitive information. Where the arrangements under our conflicts of interest policy are not sufficient to manage a particular conflict, Degroof Petercam will inform the relevant client of the nature of the conflict so that the client can make a well-informed decision. Next to the aforementioned arrangements, Degroof Petercam has also implemented the internal arrangements required by article 37(1) of the Commission Delegated Regulation 2017/565.

**No offer**

This report does not constitute and should not be construed as, an offer or solicitation for the sale, purchase or subscription of any financial instrument. Any offer or entry into any transaction requires Degroof Petercam's subsequent formal agreement which may be subject to internal approvals and execution of binding transaction documents.

**No investment advice**

The information contained in this report should not be regarded as personalized and should not be considered as a recommendation of investment advice. Recipients should not construe the content of this report as legal, tax, accounting or investment advice or personal recommendation. Accordingly Degroof Petercam is under no obligation to, and shall not, determine the suitability for the recipient of any potential transaction described herein. Recipients should seek advice to their advisors in order to determine the merits, terms, conditions and risks of any potential transaction that may be described herein.

**Forward looking statements**

This report may contain forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the actual results, condition, performance, prospects, growth or opportunities to differ materially from those expressed in, or suggested by, these forward-looking statements. Forward-looking statements are not guarantees of future performance and there is no guarantee that any of the estimates or projections will be achieved. Actual results may vary from the projections and such variation may be material.

**Past & simulated past performance**

Any past or simulated past performance including back-testing, modelling or scenario analysis contained herein is no indication as to future performance. No representation is made as to the accuracy of the assumptions made within, or completeness of, any modelling, scenario analysis or back-testing.

**Valuation method**

Our target valuation is generally based on a combination of valuation methods including DCF, SOTP, peer group comparison, historical ratio analysis and others. The outcome of these valuation methods is sensitive to both external factors (e.g. interest rates and market valuations) and assumptions we make (e.g. on sales growth, profitability, or valuation discounts). Be aware that even small changes in these elements can lead to large changes in target valuation. More information on the valuation method used for this company can be found in the reports published on <https://www.degroofpetercam.com/en-be/commissioned-research>

**No liability**

Degroof Petercam accepts no liability whatsoever for any direct or consequential loss or damage arising from any use of this report or its content. This report does not purport to give an exhaustive description of the financial instrument and of the issuer of the financial instrument it relates to. Although all reasonable care has been taken to ensure that the information in this report is accurate, neither Degroof Petercam, nor any of its affiliated companies, directors, advisors or employees can be held liable for any incorrect, incomplete or missing information, or for any direct or indirect damage, losses, costs, claims, liabilities or other expenses which would result from the use of, or reliance on, this report, except in case of willful misconduct or gross negligence. The information contained in this report has not been independently verified by any independent third party.

**Distribution restriction**

The present report is exclusively intended to professional clients and eligible counterparties, to the exclusion of retail clients. It may not be copied, reproduced, marketed or distributed in whole or in part for any purpose whatsoever without the prior written consent of Degroof Petercam.

The present report may not be taken or transmitted or distributed, directly or indirectly, outside of the EEA (but for the United Kingdom).

## Report completion and updates

This report was first disseminated by Degroof Petercam on 31 August 2022 08:39 CET

Valuations are continuously reviewed by the analyst and will be updated and/or refreshed regularly. The rationale behind a change in target valuation will be explained in such a refresher/update.

An overview of the research published on this company can be found on our website: <https://www.degroofpetercam.com/en-be/commissioned-research> This website will also give you access to all of the commissioned research reports that have been disseminated during the preceding 12-month period.

This report has not been reviewed by the company prior to publication.

The report has been reviewed by Vivien Maquet, Equity Analyst.

# Degroof Petercam Global Markets

www.degroofpetercam.com

Nijverheidsstraat / Rue de l'Industrie 44 – 1040 Brussels

De Entrée 238 A 7<sup>th</sup> floor – 1101 EE Amsterdam

**Benoît Mortelmans** +32 2 662 82 93

## Equity Research / Analysts

<b>Fernand de Boer</b>	Retail/Food & Beverages	+31 20 573 5417
<b>Kris Kippers</b>	Consumer Goods/Holdings	+32 2 287 9259
Frank Claassen	Industrials	+31 20 573 5409
Christophe Dombu Youta, PhD	Biotech/Healthcare	+32 2 287 9051
Vivien Maquet	Telecom/Utilities/Real Estate	+32 2 662 8446
Inna Maslova	Real Estate	+32 2 662 8644
Laura Roba	ESG/Medtech	+32 2 287 9276
Michael Roeg	Technology	+31 20 573 5422
David Seynnaeve, PhD	Biotech/Healthcare	+32 2 287 9771
Joren Van Aken	Holdings/Misc.	+32 2 662 8883
Luuk van Beek	Energy/Engineering/Construction	+31 20 573 5471
Herman van der Loos, CFA	Real Estate	+32 2 662 8304
Christel De Clerck	Support & Editing	+32 2 662 8302

## Corporate Brokerage & Syndication

<b>Gert Potvlieghe</b>		+32 2 662 8289
Raymond de Wolff		+31 20 573 5414
Tineke Hosselaer	Corporate access	+32 2 662 8290
Charlotte Mertens	Corporate access	+31 20 573 5416

## Sales

<b>Anthony della Faille</b>	+32 2 662 8724
<b>Laurent Pierret</b>	+32 2 662 8654

## Equity Sales

<b>Simon Vlamincq</b>	+32 2 662 8291
<b>Damien Fontaine</b>	+32 2 662 8287
Assia Adanouj	+32 2 662 8768
Piethain Leune	+31 20 573 5436
Jeroen Van Genuchten	+31 20 573 5428
Beatrice Leysens - Assistant	+32 2 662 8262

## Sales Trading

<b>Veronique De Schoemaecker</b>	+32 2 662 8280
Pieter De Moerloose	+32 2 662 8870
Fabrice Faccenda	+32 2 662 8986
Frédéric Lebrun	+32 2 287 9190

## Fixed Income Sales

<b>An-Sofie Meirsschaut</b>	+32 2 662 8665
Olivier Gigounon	+32 2 287 9184
Lieven Krikilion	+32 2 287 9559
Sandra Timmermans	+32 2 662 8852

## Derivatives

<b>Karim Marrakchi</b>	+32 2 662 8940
Eric Debeaud	+32 2 287 9827
Thierry De Wispelaere	+32 2 662 8674